Chris Schott Recent News
Recent Deals, Pipeline Updates Setting Up AbbVie For Long-Term Growth
New Upside Potential Drives JPMorgan's Eli Lilly Upgrade
Valeant Gets First Downgrade In Over 3 Months
JPMorgan's Take On Big Pharma's New ASCO Abstracts
JPMorgan On Allergan: Solid Core Product Performance
Pfizer's Valuation Is Attractive, And JPMorgan Wouldn't Be Surprised To See A Breakup
JPMorgan Isn't Concerned About Valeant's Ad Hoc Committee At All; Says Sum-Of-The-Parts Shows Upside
Some On Wall Street Still Back Valeant
Valeant Has More Volatility Coming, JPMorgan Says
Pfizer, Allergan In 'Final Innings' Of Merger Talks
Time To Buy Mylan's Clear Path To EPS Upside, JP Morgan Says
How Allergan Could Be Pfizer's Rocket Ship
Wall Street Defends AbbVie, Says Reaction Is Overdone
Calls Of Note: The Street's Research Moving Stocks This Monday
Analyst Finds Perrigo 'Still Attractive' As Take Out Target
JPMorgan Says Mylan Has 3 Paths To Upside
Will Actavis Win Competition For Allergan's Affection?
Pfizer Inc. Is Kicking The Tires At Actavis PLC
UPDATE: JP Morgan Upgrades Teva Pharmaceuticals
UPDATE: J.P. Morgan Downgrades Teva Pharmaceutical on Too Much Uncertainty Following CEO Departure
UPDATE: J.P. Morgan Upgrades Bristol-Myers Squibb Ahead of Multiple Important Catalysts
UPDATE: J.P. Morgan Downgrades Teva, Says No Near-Term Upside in Sight
J.P. Morgan Reiterates Overweight Rating on Zoetis Following Prizer Share Exchange